Topical Skin Agents for Diabetic and Aged Tissue Restoration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Skin pathologies associated with diabetes and aging, such as dry, thin skin with compromised elasticity and impaired immune response, are not effectively addressed by existing treatments, leading to severe inflammatory responses and structural impairments.
Innovation Solution
Topical administration of agents like PKC isoform modulators, adipokines, PPARγ, and insulin signaling pathway modulators to restore impaired skin physiological conditions, promoting skin rejuvenation and revitalization by influencing insulin signaling, adipocyte function, and dermal matrix formation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing treatments are used for diabetic and aged skin, then treatment simplicity is maintained, but skin structure restoration and function improvement are insufficient
Solution Approach 1:
The treatment composition is segmented into multiple distinct modules: insulin signaling pathway modulators (e.g., insulin, IGF-1), adipokines (e.g., adiponectin, leptin), PPARγ agonists (e.g., rosiglitazone), and growth factors (e.g., TGF-β, PDGF). Each module targets specific physiological pathways impaired in diabetic and aged skin, allowing comprehensive restoration through coordinated action of specialized components.
Solution Approach 2:
The invention employs a composite treatment formulation combining multiple bioactive agents with different mechanisms of action. This composite approach integrates molecules that regulate insulin signaling, adipocyte function, inflammation, and extracellular matrix synthesis, creating a synergistic effect that restores skin structure and function more effectively than single-agent treatments.
2Strength
If insulin signaling pathway modulators are administered, then skin elasticity and strength are improved, but treatment cost increases
Solution Approach 1:
The treatment composition uses multi-functional bioactive agents that simultaneously address multiple aspects of skin pathology. For example, insulin and IGF-1 not only improve skin elasticity and strength through collagen synthesis but also regulate glucose metabolism and inhibit inflammation. PPARγ agonists simultaneously affect adipocyte differentiation, inflammation reduction, and extracellular matrix production, providing comprehensive benefits from single agents.
Solution Approach 2:
The invention optimizes the concentration and dosage parameters of each bioactive agent to achieve therapeutic effects at cost-effective levels. By carefully controlling the parameters of insulin signaling modulators, adipokines, and PPARγ agonists, the treatment achieves significant skin strength improvement while minimizing unnecessary expenditure on excessive dosing.
3Object-affected harmful factors
If topical agents are administered to restore skin physiology, then inflammation is reduced, but treatment duration increases
Solution Approach 1:
The treatment composition includes agents that preliminarily address the root causes of chronic inflammation in diabetic and aged skin. Insulin signaling modulators and PPARγ agonists are administered early in the treatment protocol to restore metabolic balance and reduce inflammatory mediators before significant tissue damage occurs, thereby shortening the overall treatment duration required to achieve anti-inflammatory effects.
Solution Approach 2:
The invention employs a continuous treatment regimen where bioactive agents are administered in sustained releases or repeated applications to maintain therapeutic concentrations throughout the treatment period. This continuous action ensures persistent anti-inflammatory effects and prevents recurrence, ultimately reducing the total treatment duration by avoiding relapses that would require additional treatment cycles.
Data Source
AI summary
Method and compositions are provided for treating or preventing a skin pathology or disorder associated with diabetes and/or aging, by topical administration of at least one agent capable of restoring an impaired physiological condition of the skin associated with said skin pathology or disorder. Examples of such agents include PKC modulating agents, various adipokines and insulin signaling related molecules. In particular, restoration of the subcutaneous adipose tissue can overcome many of the diabetic skin pathologies and aging skin disorders and conditions.